ClinicalTrials.gg

Program

nogapendekin alfa inbakicept

Also written as “ALT-803”, “N-803” and “Nogapendekin alfa inbakicept (NAI)”.

Its studies are mostly in Pancreatic Neoplasms · Carcinoma, Non-Small-Cell Lung · Non-Muscle Invasive Bladder Neoplasms · Triple Negative Breast Neoplasms · Carcinoma, Transitional Cell, led by ImmunityBio.

Furthest: phase 3, since Jan 13, 201745 company-led studies, 11 open or runningNext primary completion: Nov 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
ImmunityBio4511 open or runningphase 3since Jan 13, 2017Sep 11, 2013Nov 2026phase 2 · NCT06829823

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 32 studies since Sep 11, 2013.

  1. Jun 26, 2023Phase 1 study in Healthy SubjectsNCT06040918 · 10 enrolled · United States
  2. Dec 17, 2024Phase 3 study in Carcinoma, Non-Small-Cell LungNCT06745908 · 507 planned · United States, Canada, United Kingdom
  3. Feb 5, 2025Phase 2 study in Non-Muscle Invasive Bladder NeoplasmsNCT06829823 · 20 planned
  4. Jul 30, 20252 phase 2 studies in Post-Acute COVID-19 SyndromeNCT07123727, NCT07108036
  5. Sep 18, 2025Phase 3 study in Community-Acquired PneumoniaNCT07492875
  6. Oct 14, 2025Phase 1 study in Carcinoma, Transitional CellNCT07217496 · 18 planned · United States
  7. Nov 20, 2025Phase 1 study in Pancreatic NeoplasmsNCT07488884
  8. Mar 26, 2026Phase 3 study in Carcinoma, Non-Small-Cell LungNCT07524257
  9. Apr 20, 2026Phase 3 study in Non-Muscle Invasive Bladder NeoplasmsNCT07551544
  10. May 5, 2026Phase 2 study in SepsisNCT07578558
  11. Jun 1, 2026Phase 2 study in Squamous Cell Carcinoma of Head and NeckNCT07628062 · 70 planned
  12. Aug 21, 2026Phase 2 study in SepsisNCT07783789 · 50 planned
  13. Sep 25, 2026Primary completion moved from 2027-10-12 to 2028-05-12Date moved laterphase 2 · +7 months · NCT07783789
  14. Nov 17, 2026Phase 2 study withdrawnStudy stoppedNCT07578558 · “Sponsor decision”

Ahead

  1. Nov 2026Primary completion: phase 2 study in Non-Muscle Invasive Bladder NeoplasmsNCT06829823
  2. Mar 2027Primary completion: phase 2 study in Post-Acute COVID-19 SyndromeNCT07123727
  3. Jan 2028Primary completion: phase 1 study in Carcinoma, Transitional CellNCT07217496
  4. May 12, 2028Primary completion: phase 2 study in SepsisNCT07783789

TargetBeta

“A fusion protein soluble complex and interleukin-15 (IL-15) receptor agonist composed of nogapendekin alfa, a mutated form of the cytokine interleukin (IL)-15 (IL-15N72D) and inbakicept, a fusion protein containing a dimeric IL-15 receptor alpha (IL-15Ra) sushi domain ”NCIt, by rule
“Interleukin-15 receptor agonist”ChEMBL 37, by rule

Studies

All 45 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07783789Sepsis2Not yet recruitingMay 12, 202850
NCT07628062Squamous Cell Carcinoma of Head and Neck2Not yet recruitingDec 31, 203070
NCT07578558Sepsis2WithdrawnAug 3, 20270
NCT07551544Non-Muscle Invasive Bladder Neoplasms3WithdrawnMay 20320
NCT07524257Carcinoma, Non-Small-Cell Lung3WithdrawnMay 15, 20290
NCT07488884Pancreatic Neoplasms1WithdrawnJun 1, 20270
NCT07217496Carcinoma, Transitional Cell · United States1Not yet recruitingJan 202818
NCT07492875Community-Acquired Pneumonia3WithdrawnApr 15, 20290
NCT07123727Post-Acute COVID-19 Syndrome · United States2RecruitingMar 202740
NCT07108036Post-Acute COVID-19 Syndrome · United States2RecruitingOct 202620
NCT06829823Non-Muscle Invasive Bladder Neoplasms2Not yet recruitingNov 202620
NCT06745908Carcinoma, Non-Small-Cell Lung · United States, Canada, United Kingdom3RecruitingSep 2028507
NCT06040918Healthy Subjects · United States1CompletedSep 3, 202410
NCT04390399Pancreatic Neoplasms · United States2Active, not recruitingOct 13, 2025328
NCT04385849COVID-19 · United States1TerminatedJul 25, 20201
NCT03853317Carcinoma, Merkel Cell · United States2TerminatedSep 29, 20219
NCT03647423Chordoma · United States2WithdrawnAug 31, 20200
NCT03586869Pancreatic Neoplasms · United States2TerminatedApr 17, 20193
NCT03574649Carcinoma, Non-Small-Cell Lung · United States2WithdrawnAug 20180
NCT03563144Pancreatic Neoplasms · United States2WithdrawnDec 30, 20190
NCT03554109Triple Negative Breast Neoplasms · United States2WithdrawnJun 20200
NCT03563170Hepatocellular Carcinoma Non-resectable · United States2WithdrawnAug 23, 20190
NCT03387111Carcinoma, Squamous Cell · United States2TerminatedApr 17, 20194
NCT03387098Pancreatic Neoplasms · United States2TerminatedSep 12, 20184
NCT03387085Triple Negative Breast Neoplasms · United States2TerminatedSep 11, 20209
NCT03381586Healthy · United States1CompletedMar 13, 201820
NCT03329248Pancreatic Neoplasms · United States2TerminatedAug 13, 20186
NCT03228667Carcinoma, Non-Small-Cell Lung · United States2Active, not recruitingAug 31, 202940
NCT03197584Ovarian Neoplasms2WithdrawnFeb 20190
NCT03197571Carcinoma, Transitional Cell2WithdrawnJan 20190
NCT03175666Triple Negative Breast Neoplasms2WithdrawnJan 20190
NCT03169790Lymphoma, Non-Hodgkin2WithdrawnJan 20190
NCT03169777Colorectal Neoplasms2WithdrawnJan 20190
NCT03169764Squamous Cell Carcinoma of Head and Neck2WithdrawnJan 20190
NCT03169738Carcinoma, Non-Small-Cell Lung2WithdrawnJan 20190
NCT03167177Melanoma2WithdrawnJan 20190
NCT03167164Carcinoma, Merkel Cell2WithdrawnJan 20190
NCT03127098Thyroid Neoplasms · United States2TerminatedDec 7, 20173
NCT03136406Pancreatic Neoplasms · United States2TerminatedNov 22, 20173
NCT03022825Urinary Bladder Neoplasms · United States3Active, not recruitingOct 1, 2024190
NCT02559674Neoplasms · United States1CompletedFeb 21, 20188
NCT02384954Recurrence · United States2TerminatedDec 13, 202043
NCT02138734Non-Muscle Invasive Bladder Neoplasms · United States, India, South Africa2Active, not recruitingSep 30, 2026369
NCT02099539Recurrence · United States1TerminatedJun 19, 201819
NCT01946789Neoplasms · United States1CompletedAug 201726

How it is read

Names in the registry

  • “ALT-803”, 21 entries
  • “N-803”, 11 entries
  • “Nogapendekin alfa inbakicept (NAI)”, 3 entries
  • “Nogapendekin Alfa Inbakicept (NAI)”, 2 entries
  • “Anktiva”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.